SOURCE-LINKED STUDY SUMMARY
Once-Weekly Semaglutide in Adolescents with Obesity.
Abstract summarizedQuality not appraised
- What was studied
- A randomized placebo-controlled trial tested weekly semaglutide plus lifestyle intervention in adolescents with obesity or qualifying overweight.
- Who / model studied
- Adolescents with obesity, or overweight plus a weight-related condition, were eligible.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Semaglutide reduced BMI more than placebo and improved several cardiometabolic risk factors. Gastrointestinal adverse events were more common with semaglutide.
- Limitations & context
- Gastrointestinal adverse events were more frequent with semaglutide, and cholelithiasis occurred only in that group.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2208601